Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL

Clinical trial NCT04494503 · RECRUITING

Trial details

NCT number: NCT04494503
Sponsor: Ascentage Pharma Group Inc.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma

Start date: 2020-08-31
Primary completion: 2024-10-20
Enrollment: 123

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.